#For researchers
Written for academic and pharma-industry researchers; assumes domain literacy.
SLIM LIVER: Semaglutide and HIV
SLIM LIVER found improved liver-fat and blood-marker results with semaglutide in people with HIV, but the trial had no control group.
α-Lactalbumin nanomicelles in obese mice
A mouse study tested sulforaphene-loaded α-lactalbumin nanomicelles against semaglutide, but it provides no human efficacy or safety evidence.
AI as a commercial health determinant
A BMJ commentary frames AI as a commercial determinant of health. Persuasion and misinformation studies show why the concern deserves testing.
Semaglutide in Animal HFpEF Models
Rat and minipig HFpEF models showed cardiac and liver changes without substantial weight loss, but they cannot establish human efficacy.
How Tirzepatide May Raise Heart Rate
A human stem-cell study links tirzepatide to faster pacemaker-cell beating through cAMP and calcium signalling, but it is not a patient trial.
A two-timepoint semaglutide brain map
A mouse study mapped semaglutide-linked activity across more than 500 brain areas using two timepoints, finding 24 engaged regions.
An oral semaglutide emulsion in rats
A lipid-based semaglutide formulation improved cell transport and glucose measures in diabetic rats, but it has not been tested in people.
GIP receptors and brain dopamine in mice
A 2026 mouse study found GIP receptors in the lateral septum, where GIP and GLP-1 agonists cut electrically evoked dopamine release.
BPC-157 for a running injury: evidence
A runner's forum question reflects real interest in BPC-157, but animal studies and anecdotes do not establish safe or effective injury treatment.
Semaglutide Plus Niacin for Lung Fibrosis
A rat study paired semaglutide with niacin against lung scarring, targeting the NAD+/SIRT1-FOXO3a-Nrf2 pathway. Here is what it does and does not show.
Why semaglutide alone beat the CRV431 combo
In a mouse model of advanced liver disease, semaglutide alone reduced tumor burden more than adding the investigational compound CRV431.
How GLP-1 Analogs Are Engineered
A 2026 review explains how GLP-1 analogs use sequence changes, peptide shape and lipidation to resist breakdown and last longer.